All In Biotech

NDA 204114 · Novartis

Mekinist

Trametinib Dimethyl Sulfoxide · Oral

NovelBreakthrough therapyAccelerated approvalOrphan

Last checked: Nov 20, 2026Latest source record: May 7, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

May 29, 2013

Approved uses

13

Original approval plus efficacy supplements

Registered trials

16

2 Phase 3, 1 recruiting

FAERS reports

24,319

17,696 serious, 5,169 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 7, 2026.

MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal...

Mechanism: Trametinib is a reversible inhibitor of mitogen-activated extracellular signal-regulated kinase 1 (MEK1) and MEK2 activation and of MEK1 and MEK2 kinase activity. MEK proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway, which promotes cellular proliferation. BRAF V600E mutations result in constitutive activation of the BRAF pathway which includes MEK1 and MEK2. Trametinib inhibits cell growth of various BRAF V600 mutation-positive tumors in vitro and in vivo. Trametinib and dabrafenib target two different kinases in the RAS/RAF/MEK/ERK pathway. Use of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 7, 2025 Supplement 34 · Efficacy OrphanLetterLabel
  • Aug 31, 2023 Supplement 29 · Efficacy · priority review OrphanLetterLabel
  • Mar 16, 2023 Supplement 25 · Efficacy · priority review OrphanLabelLetter
  • Jun 22, 2022 Supplement 24 · Efficacy · priority review OrphanLabelLetter
  • May 27, 2022 Supplement 23 · Efficacy LetterLabel
  • Jan 28, 2022 Supplement 19 · Efficacy OrphanLetterLabel
  • Oct 6, 2019 Supplement 12 · Efficacy OrphanLabelLetter
  • May 4, 2018 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Apr 30, 2018 Supplement 7 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jun 22, 2017 Supplement 5 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Nov 20, 2015 Supplement 4 · Efficacy · priority review OrphanLabelLetter
  • Jan 8, 2014 Supplement 1 · Efficacy · priority review Accelerated approvalOrphanLabelLetter
  • May 29, 2013 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanReviewLabelOther
3 products under this application
  • MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 2MG · TABLET, ORAL · Prescription · TE AB
  • MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 0.5MG · TABLET, ORAL · Prescription · TE AB
  • MEKINIST · TRAMETINIB DIMETHYL SULFOXIDE EQ 1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Trametinib Dimethyl Sulfoxide" as an intervention, any sponsor and status, largest first.

All 16 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pyrexia4,116
  • death3,413
  • malignant neoplasm progression2,070
  • rash1,764
  • fatigue1,538
  • nausea1,512
  • diarrhoea1,308
  • chills1,303
  • product use in unapproved indication1,091
  • vomiting1,083
  • off label use873
  • headache771

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2013360
2014628
20151,693
20161,422
20171,760
20182,350
20192,676
20202,470
20212,414
20222,233
20232,150
20241,731
20251,525
2026907

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Mekinist (Trametinib Dimethyl Sulfoxide)

2024 spending

$207M

Beneficiaries

2,654

14,526 claims

Per beneficiary

$77,997

$399.06 per unit

View as table
YearSpending
2020$113,841,286
2021$136,778,622
2022$159,068,731
2023$173,398,802
2024$207,005,041

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.